This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

LifeMap Sciences, A Subsidiary Of BioTime, Announces Release Of GeneCards® Version 3.11

LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today the release of GeneCards ®, Version 3.11. The new release is available at www.genecards.org. GeneCards ® is a comprehensive online database that provides comprehensive information on all human genes. It is accessed by professionals in many institutions including academia, research hospitals, patent offices, and leading biotech and pharma companies. LifeMap Sciences holds the exclusive worldwide license to market GeneCards ® from Yeda Research and Development Company Ltd., the commercial arm of the Weizmann Institute of Science.

GeneCards ® 3.11 now showcases gene-related scientific conferences, including links to ESCMID 2014 on Microbiology & Infectious Diseases, AD/PD 2014 on Alzheimer’s and Parkinson’s disease and ISPPD-9 on Pneumococci and Pneumococcal diseases.

Additional features of the new GeneCards ® release include:

  • More than 122,000 gene entries, including the world’s largest arsenal of ~77,000 non-protein-coding RNAs.
  • Revamped comprehensive version of the popular disease-gene list with links to MalaCards ( www.malacards.org), our Human Disease Compendium.
  • Enhanced information about genetic variations and disease mutations from UniProtKB
  • Gene classifications from HGNC and IUPHAR
  • Information on protein-binding ligands from the International Union of Basic and Clinical Pharmacology (IUPHAR)
  • Enhanced proteomics section with new tissue expression data from the renown MAXQB
  • Improved presentation of expression in embryonic tissues from LifeMap Discovery™ ( discovery.lifemapsc.com) and new antibodies.

“It is a pleasure to see GeneCards making new progress in its mission to cover ‘all about human genes’. I am especially proud to see the new information from the International Union of Basic and Clinical Pharmacology, covering both gene-related binding molecules (ligands) and protein classification. Along with our newly enhanced super-pathways and novel proteome data, these items portray the inventiveness of our academic team,” said Professor Doron Lancet, Ph.D., The Ralph D. and Lois R. Silver Professor of Human Genomics, at the Weizmann Institute of Science.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,880.36 -31.75 -0.19%
S&P 500 1,970.07 +0.12 0.01%
NASDAQ 4,462.9020 +20.2040 0.45%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs